← Back to Clinical Trials
Recruiting NCT06017557

Predicting Outcome of Cytoreduction in Advanced Ovarian Cancer

Trial Parameters

Condition Ovarian Cancer Stage III
Sponsor Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Study Type INTERVENTIONAL
Phase N/A
Enrollment 151
Sex FEMALE
Min Age 18 Years
Max Age N/A
Start Date 2023-01-02
Completion 2025-12-15
Interventions
Artificial Intelligence

Brief Summary

PREDAtOOR is a pilot study and this study aims at improving the selection of the best treatment strategy for patients with advanced ovarian cancer by using Camera Vision (CV) to predict outcomes of cyto reduction at the time of Diagnostic laparoscopy.

Eligibility Criteria

Inclusion Criteria: * Patients treated at Fondazione Policlinico Gemelli Hospital, Rome Italy, Trillium -Credit Valley Hospital, Mississauga, Ontario and Princess Margaret Cancer Centre, Toronto, Canada * Patients fit for cytoreductive surgery * Patients with a primary diagnosis of suspect Stage III-IV ovarian cancer * Patients selected for interval cytoreductive surgery after NACT Exclusion Criteria: * Patients with pre-operative Stage I-II disease confined to the pelvis * Patients unfit for surgery * Lack of information about patients' surgical outcomes and clinicopathological characteristics * LGSOC, Clear cell and mucinous, non-epithelial histologic subtypes (if available)

Related Trials